News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,688 Results
Type
Article (14902)
Company Profile (299)
Press Release (266481)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79835)
Career Advice (162)
Deals (13337)
Drug Delivery (39)
Drug Development (50702)
Employer Resources (31)
FDA (5837)
Job Trends (5167)
News (145079)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (82)
Alliances (21761)
ALS (126)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (242)
Approvals (6031)
Artificial intelligence (262)
Autoimmune disease (115)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (345)
Cancer (3138)
Cardiovascular disease (238)
Career advice (147)
Career pathing (7)
CAR-T (221)
CDC (5)
Cell therapy (568)
Cervical cancer (14)
Clinical research (43690)
Collaboration (1157)
Company closure (2)
Compensation (597)
Complete response letters (40)
COVID-19 (1101)
CRISPR (86)
C-suite (559)
Cystic fibrosis (112)
Data (4339)
Denatured (15)
Depression (93)
Diabetes (255)
Diagnostics (1380)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (193)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31649)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51680)
Executive appointments (625)
FDA (7595)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (989)
Gene editing (182)
Generative AI (22)
Gene therapy (492)
GLP-1 (506)
Government (1148)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (192)
Immuno-oncology (42)
Indications (66)
Infectious disease (1206)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7346)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (423)
Lymphoma (250)
Machine learning (24)
Management (7)
Manufacturing (377)
MASH (130)
Medical device (2663)
Medtech (2672)
Mergers & acquisitions (6618)
Metabolic disorders (729)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1958)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (332)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (334)
Peanut (43)
People (26667)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15480)
Phase 2 (20302)
Phase 3 (12823)
Pipeline (3289)
Policy (90)
Postmarket research (853)
Preclinical (6536)
Press Release (30)
Prostate cancer (146)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (655)
Real estate (1448)
Recruiting (12)
Regulatory (9905)
Reports (19)
Research institute (972)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (336)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (72)
Last 7 days (350)
Last 30 days (1240)
Last 365 days (17862)
2026 (1777)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18260)
Australia (3111)
California (7096)
Canada (1843)
China (777)
Colorado (248)
Connecticut (252)
Delaware (236)
Europe (39187)
Florida (905)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (36)
Indiana (161)
Iowa (8)
Japan (225)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5601)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1649)
New Mexico (13)
New York (1768)
North Carolina (831)
North Dakota (6)
Northern California (3488)
Ohio (179)
Oklahoma (11)
Oregon (24)
Pennsylvania (1282)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2814)
Tennessee (40)
Texas (910)
United States (23402)
Utah (97)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (46)
281,688 Results for "iomx therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024
iOmx Therapeutics AG announces that it will present new data on its lead I/O drug candidates OMX-0407 and IOMX-0675, plus its proprietary iOTarg™ screening platform at the upcoming American Association for Cancer Research Annual Meeting 2024 taking place from April 5-10, 2024, in San Diego, California.
April 3, 2024
·
5 min read
iOmx Therapeutics appoints Dr. Nils Peter Debus as Chief Business Officer
iOmx Therapeutics AG (iOmx), a clinical stage biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the appointment of Dr. Nils Peter Debus as Chief Business Officer
September 5, 2023
·
2 min read
Press Releases
iOmx Therapeutics Initiates Phase Ib with OMX‑0407
August 23, 2024
·
4 min read
iOmx Therapeutics appoints Professor Frances Balkwill to the Scientific Advisory Board
iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, today announced the appointment of Frances Balkwill, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, to its Scientific Advisory Board (SAB).
September 8, 2022
·
3 min read
iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023
iOmx Therapeutics AG today announced that its high-throughput target discovery platform, myeloid iOTargTM, will be highlighted in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.
March 15, 2023
·
4 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
iOmx Therapeutics Raises EUR 65 million in Series B Round
iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, announced the closing of a Series B round totaling EUR 65 million.
October 5, 2021
·
6 min read
Drug Development
iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022
iOmx Therapeutics AG, a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, announced the presentation of new preclinical data for its lead program IMT-07 with product candidate OMX-0407, a first-in-class oral SIK3 inhibitor.
April 7, 2022
·
3 min read
iOmx Therapeutics Announces Dosing of First Patient with SIK Inhibitor OMX-0407 in Phase I Clinical Trial
First-in-human trial to test safety and tolerability of a novel immune-protective kinase inhibitor in multiple solid tumors. First iOTarg platform-derived product candidate in the clinic.
April 5, 2023
·
3 min read
Press Releases
Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
January 26, 2026
·
4 min read
1 of 28,169
Next
